These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30536143)

  • 1. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
    Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
    Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
    Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
    J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries.
    van Akkooi ACJ; Haferkamp S; Papa S; Franke V; Pinter A; Weishaupt C; Huber MA; Loquai C; Richtig E; Gokani P; Öhrling K; Louie KS; Mohr P
    Adv Ther; 2021 Feb; 38(2):1245-1262. PubMed ID: 33368016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
    Garnock-Jones KP
    BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
    Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T
    Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
    Harrington KJ; Andtbacka RH; Collichio F; Downey G; Chen L; Szabo Z; Kaufman HL
    Onco Targets Ther; 2016; 9():7081-7093. PubMed ID: 27895500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
    Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
    Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
    Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
    J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
    Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
    Chitnis SD; Seim NB; Kendra K
    J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
    Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
    Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
    Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
    Dummer R; Hoeller C; Gruter IP; Michielin O
    Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
    Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG
    BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
    Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
    Burke EE; Zager JS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
    Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
    Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.